BRIEF-AstraZeneca To Transfer Rights To Eklira, Duaklir to Covis Pharma
Nov 1 (Reuters) - AstraZeneca:
* ASTRAZENECA PLC - ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR
* ASTRAZENECA - AGREEMENT SHARPENS ASTRAZENECA'S FOCUS ON PRIORITY MEDICINES IN RESPIRATORY & IMMUNOLOGY PORTFOLIO
* ASTRAZENECA - ASTRAZENECA TO TRANSFER GLOBAL RIGHTS FOR EKLIRA AND DUAKLIR TO COVIS PHARMA
* ASTRAZENECA - BOTH MEDICINES ARE DELIVERED VIA GENUAIR DEVICE AND USED FOR TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
* ASTRAZENECA - COVIS PHARMA WILL PAY ASTRAZENECA $270M ON COMPLETION
* ASTRAZENECA - COVIS PHARMA WILL ALSO COVER CERTAIN ONGOING DEVELOPMENT COSTS RELATED TO MEDICINES
* ASTRAZENECA - IN 2020, EKLIRA AND DUAKLIR GENERATED ASTRAZENECA REVENUE OF $143M IN COUNTRIES COVERED BY THIS AGREEMENT
* ASTRAZENECA - AGREEMENT WILL NOT IMPACT COMPANY'S FINANCIAL GUIDANCE FOR 2021 Source text for Eikon: Further company coverage:
